Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have fou...

Source: Cardiovascular Diabetology - July 17, 2018 Category: Cardiology Authors: Ghadeer K. Dawwas, Steven M. Smith and Haesuk Park Tags: Original investigation Source Type: research